文献速递核素与放射性配体治疗

膀胱内[90Y]DOTA-生物素-亲和素放疗对非肌层浸润性膀胱癌的初步疗效

Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-11-09

本研究在动物模型中评估膀胱内给予[90Y]DOTA-生物素-亲和素([90Y]DBA)治疗非肌层浸润性膀胱癌的可行性。结果显示DBA膀胱内滞留可达4小时,单次[90Y]DBA放疗显著抑制MB49膀胱癌生长,且第10天未造成尿路上皮短期损伤。作者认为[90Y]DBA膀胱内治疗NMIBC具有潜力。

要点

  • 膀胱内灌注[68Ga]DBA后,DBA在膀胱内滞留时间可达4小时。
  • 单次9.2 MBq [90Y]DBA膀胱内治疗显著抑制小鼠MB49膀胱癌生长。
  • 第10天免疫组化显示[90Y]DBA未造成尿路上皮短期损伤,形态与健康小鼠正常尿路上皮相似。

核心结论

  • 作者认为膀胱内[90Y]DBA有望成为非肌层浸润性膀胱癌的一种治疗方法。

研究设计与样本

  • 研究在动物模型中通过68Ga标记DBA行动态microPET显像及离体器官γ计数,评估膀胱内DBA的生物分布。
  • 抗肿瘤活性在原位MB49小鼠膀胱癌模型中评估,小鼠接种表达荧光素酶的MB49细胞后3天经膀胱内给予9.2 MBq [90Y]DBA或未标记DBA。
  • 通过生物发光成像监测膀胱肿瘤生长,并用免疫组化分析膀胱形态评估[90Y]DBA对尿路上皮组织学的影响。

主要发现

  • DBA在膀胱内灌注后滞留时间可达4小时。
  • 单次[90Y]DBA放疗显著抑制MB49膀胱癌生长。
  • 将90Y-DOTA-生物素连接至亲和素可防止其被重新吸收入血并分布至全身其他部位。
  • 免疫组化显示[90Y]DBA放疗后第10天未造成尿路上皮短期损伤,表现与健康小鼠正常尿路上皮相似。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bladder cancer represents 3% of all new cancer diagnoses per year. We propose intravesical radionuclide therapy using the β-emitter 90Y linked to DOTA-biotin-avidin ([90Y]DBA) to deliver short-range radiation against non-muscle invasive bladder cancer (NMIBC). MATERIAL AND METHODS: Image-guided biodistribution of intravesical DBA was investigated in an animal model by radiolabeling DBA with the 68Ga and dynamic microPET imaging following intravesical infusion of [68Ga]DBA for up to 4 h and post-necropsy γ-counting of organs. The antitumor activity of [90Y]DBA was investigated using an orthotopic MB49 murine bladder cancer model. Mice were injected with luciferase-expressing MB49 cells and treated via intravesical administration with 9.2 MBq of [90Y]DBA or unlabeled DBA 3 days after the tumor implantation. Bioluminescence imaging was conducted after tumor implantation to monitor the bladder tumor growth. In addition, we investigated the effects of [90Y]DBA radiation on urothelial histology with immunohistochemistry analysis of bladder morphology. RESULTS: Our results demonstrated that DBA is contained in the bladder for up to 4 h after intravesical infusion. A single dose of [90Y]DBA radiation treatment significantly reduced growth of MB49 bladder carcinoma. Attaching 90Y-DOTA-biotin to avidin prevents its re-absorption into the blood and distribution throughout the rest of the body. Furthermore, immunohistochemistry demonstrated that [90Y]DBA radiation treatment did not cause short-term damage to urothelium at day 10, which appeared similar to the normal urothelium of healthy mice. CONCLUSION: Our data demonstrates the potential of intravesical [90Y]DBA as a treatment for non-muscle invasive bladder cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Alì A, Leibowitz D, Bhatt N, et al. Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 36350400. doi:10.1007/s00259-022-06027-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。